682.4K XNAS Volume
XNAS 19 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 14 Mar 2025 | 37,564 | 1,039,642 (1%) | 0% | 10.1 | 378,269 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 14 Mar 2025 | 30,118 | 1,009,524 (1%) | 0% | 10.1 | 303,288 | Common Stock |
| Mark S. Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 99,227 | 401,262 (0%) | 0% | 0 | Common Stock | |
| Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 5,847 | 395,415 (0%) | 0% | 10.1 | 58,879 | Common Stock |
| Mark S. Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 3,729 | 391,686 (0%) | 0% | 10.1 | 37,551 | Common Stock |
| Samraat S. Raha | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 216,495 | 488,889 (0%) | 0% | 0 | Common Stock | |
| Samraat S. Raha | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 7,649 | 481,240 (0%) | 0% | 10.1 | 77,025 | Common Stock |
| Scott J. Leffler | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 6,217 | 218,393 (0%) | 0% | 10.1 | 62,605 | Common Stock |
| Scott J. Leffler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 72,165 | 224,610 (0%) | 0% | 0 | Common Stock | |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 3,417 | 132,878 (0%) | 0% | 10.1 | 34,409 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 1,572 | 131,306 (0%) | 0% | 10.1 | 15,830 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 54,124 | 136,295 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 54,124 | 195,448 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 4,390 | 191,058 (0%) | 0% | 10.1 | 44,207 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 3,335 | 187,723 (0%) | 0% | 10.1 | 33,583 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,000 | 50,575 (0%) | 0% | 0 | Common Stock | |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 684 | 49,036 (0%) | 0% | 10.1 | 6,888 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 855 | 49,720 (0%) | 0% | 10.1 | 8,610 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 4,764 | 180,231 (0%) | 0% | 10.1 | 47,973 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 75,773 | 193,539 (0%) | 0% | 0 | Common Stock | |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 8,544 | 184,995 (0%) | 0% | 10.1 | 86,038 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.74 per share. | 25 Feb 2025 | 2,697 | 75,703 (0%) | 0% | 11.7 | 31,663 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.74 per share. | 25 Feb 2025 | 1,016 | 128,566 (0%) | 0% | 11.7 | 11,928 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 114,828 | 1,077,206 (1%) | 0% | 0 | Common Stock | |
| Mark S. Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 12,758 | 302,035 (0%) | 0% | 0 | Common Stock | |
| Margaret Ancona | SVP, Chief of Staff | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 6,468 | 82,171 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 12,758 | 141,324 (0%) | 0% | 0 | Common Stock | |
| Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 10,622 | 117,766 (0%) | 0% | 0 | Common Stock | |
| Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 3,316 | 46,575 (0%) | 0% | 0 | Common Stock | |
| Scott J. Leffler | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.54 per share. | 29 Jan 2025 | 12,230 | 152,445 (0%) | 0% | 12.5 | 153,364 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.71 per share. | 01 Jan 2025 | 417 | 107,144 (0%) | 0% | 13.7 | 5,717 | Common Stock |
| Samraat S. Raha | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 11 Dec 2024 | 29,578 | 272,394 (0%) | 0% | 14.5 | 429,177 | Common Stock |
| Mark Davis | Director | 10 Dec 2024 | 22,816 | 22,816 (0%) | 0% | 0 | Common Stock | ||
| Samraat S. Raha | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 13.83 per share. | 30 Nov 2024 | 1,118 | 301,972 (0%) | 0% | 13.8 | 15,462 | Common Stock |
| Diaz Paul J. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.93 per share. | 11 Oct 2024 | 15,000 | 962,378 (1%) | 0% | 22.9 | 343,950 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 5,004 | 289,277 (0%) | 0% | 24.4 | 121,947 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 3,359 | 294,281 (0%) | 0% | 24.4 | 81,859 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 2,515 | 129,582 (0%) | 0% | 24.4 | 61,291 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 452 | 107,561 (0%) | 0% | 24.4 | 11,015 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.64 per share. | 21 Sep 2024 | 1,075 | 297,640 (0%) | 0% | 27.6 | 29,713 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.64 per share. | 21 Sep 2024 | 966 | 78,400 (0%) | 0% | 27.6 | 26,700 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.64 per share. | 21 Sep 2024 | 964 | 43,259 (0%) | 0% | 27.6 | 26,645 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.72 per share. | 11 Sep 2024 | 15,000 | 977,378 (1%) | 0% | 26.7 | 400,800 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 11 Sep 2024 | 2,100 | 108,013 (0%) | 0% | 26.2 | 54,961 | Common Stock |
| Heiner Dreismann | Director | Sale of securities on an exchange or to another person at price $ 27.05 per share. | 09 Sep 2024 | 10,000 | 121,648 (0%) | 0% | 27.1 | 270,520 | Common Stock |
| Colleen F. Reitan | Director | Sale of securities on an exchange or to another person at price $ 27.95 per share. | 03 Sep 2024 | 46,012 | 42,533 (0%) | 0% | 27.9 | 1,285,851 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.12 per share. | 25 Aug 2024 | 217 | 44,223 (0%) | 0% | 28.1 | 6,102 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Sale of securities on an exchange or to another person at price $ 27.82 per share. | 21 Aug 2024 | 11,538 | 79,366 (0%) | 0% | 27.8 | 320,987 | Common Stock |
| Rashmi Kumar | Director | Sale of securities on an exchange or to another person at price $ 28.01 per share. | 19 Aug 2024 | 7,500 | 77,392 (0%) | 0% | 28.0 | 210,075 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.18 per share. | 13 Aug 2024 | 22,808 | 1,043,358 (1%) | 0% | 28.2 | 642,729 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.18 per share. | 13 Aug 2024 | 50,980 | 992,378 (1%) | 0% | 28.2 | 1,436,616 | Common Stock |
| Heiner Dreismann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 131,648 (0%) | 0% | 0 | Common Stock | |
| Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 40,145 (0%) | 0% | 0 | Common Stock | |
| S. Louise Phanstiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 127,648 (0%) | 0% | 0 | Common Stock | |
| Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 86,010 (0%) | 0% | 0 | Common Stock | |
| Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 88,545 (0%) | 0% | 0 | Common Stock | |
| Lee N. Newcomer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 82,345 (0%) | 0% | 0 | Common Stock | |
| Rashmi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 84,892 (0%) | 0% | 0 | Common Stock | |
| Daniel K. Spiegelman | Director | Sale of securities on an exchange or to another person at price $ 22.05 per share. | 03 Jun 2024 | 3,788 | 32,917 (0%) | 0% | 22.0 | 83,525 | Common Stock |
| Daniel K. Spiegelman | Director | Sale of securities on an exchange or to another person at price $ 22.04 per share. | 03 Jun 2024 | 3,788 | 36,705 (0%) | 0% | 22.0 | 83,488 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.07 per share. | 13 May 2024 | 75,000 | 1,066,166 (1%) | 0% | 25.1 | 1,880,415 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.21 per share. | 13 May 2024 | 95,000 | 1,141,166 (1%) | 0% | 25.2 | 2,394,798 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.13 per share. | 13 May 2024 | 57,844 | 1,236,166 (1%) | 0% | 25.1 | 1,453,550 | Common Stock |
| Lee N. Newcomer | Director | Sale of securities on an exchange or to another person at price $ 25.30 per share. | 13 May 2024 | 6,200 | 66,650 (0%) | 0% | 25.3 | 156,860 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.55 per share. | 14 Apr 2024 | 1,076 | 298,715 (0%) | 0% | 19.6 | 21,036 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.55 per share. | 14 Apr 2024 | 940 | 110,113 (0%) | 0% | 19.6 | 18,377 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.26 per share. | 06 Apr 2024 | 581 | 44,440 (0%) | 0% | 20.3 | 11,771 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.98 per share. | 25 Mar 2024 | 363 | 45,021 (0%) | 0% | 22.0 | 7,979 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 20,202 | 1,339,832 (1%) | 0% | 22.2 | 449,292 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 27,233 | 1,294,010 (1%) | 0% | 22.2 | 605,662 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 18,589 | 1,321,243 (1%) | 0% | 22.2 | 413,419 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,661 | 301,375 (0%) | 0% | 22.2 | 36,941 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,648 | 303,036 (0%) | 0% | 22.2 | 36,652 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,584 | 299,791 (0%) | 0% | 22.2 | 35,228 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 730 | 90,904 (0%) | 0% | 22.2 | 16,235 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,718 | 132,097 (0%) | 0% | 22.2 | 38,208 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,172 | 133,815 (0%) | 0% | 22.2 | 26,065 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,685 | 134,987 (0%) | 0% | 22.2 | 37,474 | Common Stock |
| Pamela Wong | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,441 | 65,002 (0%) | 0% | 22.2 | 32,048 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 382 | 111,614 (0%) | 0% | 22.2 | 8,496 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 561 | 111,053 (0%) | 0% | 22.2 | 12,477 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,405 | 111,996 (0%) | 0% | 22.2 | 31,247 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 401 | 45,964 (0%) | 0% | 22.2 | 8,918 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 580 | 45,384 (0%) | 0% | 22.2 | 12,899 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 363 | 46,365 (0%) | 0% | 22.2 | 8,073 | Common Stock |
| Pamela Wong | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 15 Mar 2024 | 2,568 | 66,443 (0%) | 0% | 21.2 | 54,339 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 246,248 | 1,390,644 (1%) | 0% | 0 | Common Stock | |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 30,610 | 1,360,034 (1%) | 0% | 21.2 | 647,708 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 58,631 | 308,370 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 3,686 | 304,684 (0%) | 0% | 21.2 | 77,996 | Common Stock |
| Samraat S. Raha | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 64,494 | 300,854 (0%) | 0% | 0 | Common Stock | |
| Scott J. Leffler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 46,095 | 163,865 (0%) | 0% | 0 | Common Stock | |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 1,585 | 91,634 (0%) | 0% | 21.2 | 33,539 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 35,178 | 93,219 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 35,178 | 139,978 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 3,306 | 136,672 (0%) | 0% | 21.2 | 69,955 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 49,250 | 116,723 (0%) | 0% | 0 | Common Stock | |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 3,322 | 113,401 (0%) | 0% | 21.2 | 70,294 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 7,500 | 46,728 (0%) | 0% | 0 | Common Stock | |
| Scott J. Leffler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 46,905 | 164,675 (0%) | 0% | 0 | Common Stock | |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.72 per share. | 25 Feb 2024 | 2,231 | 58,041 (0%) | 0% | 22.7 | 50,688 | Common Stock |
| Haas Kevin Richard | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.72 per share. | 25 Feb 2024 | 881 | 104,800 (0%) | 0% | 22.7 | 20,016 | Common Stock |
| J. Scott Leffler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 117,770 | 117,770 (0%) | 0% | 0 | Common Stock | |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.14 per share. | 01 Jan 2024 | 303 | 67,473 (0%) | 0% | 19.1 | 5,799 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.09 per share. | 01 Dec 2023 | 30,000 | 291,812 (0%) | 0% | 19.1 | 572,835 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.70 per share. | 25 Aug 2023 | 218 | 29,228 (0%) | 0% | 17.7 | 3,859 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.89 per share. | 13 Aug 2023 | 51,292 | 1,144,396 (1%) | 0% | 17.9 | 917,614 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.89 per share. | 13 Aug 2023 | 22,943 | 1,195,688 (1%) | 0% | 17.9 | 410,450 | Common Stock |
| Daniel K. Spiegelman | Director | Sale of securities on an exchange or to another person at price $ 23.01 per share. | 01 Jun 2023 | 8,638 | 40,493 (0%) | 0% | 23.0 | 198,760 | Common Stock |
| Daniel K. Spiegelman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 49,131 (0%) | 0% | 0 | Common Stock | |
| Heiner Dreismann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 115,953 (0%) | 0% | 0 | Common Stock | |
| Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 7,575 | 24,450 (0%) | 0% | 0 | Common Stock | |
| S. Louise Phanstiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 111,953 (0%) | 0% | 0 | Common Stock | |
| Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 70,315 (0%) | 0% | 0 | Common Stock | |
| Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 72,850 (0%) | 0% | 0 | Common Stock | |
| Lee N. Newcomer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 72,850 (0%) | 0% | 0 | Common Stock | |
| Rashmi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,151 | 69,197 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 14 Apr 2023 | 703 | 262,704 (0%) | 0% | 22.3 | 15,656 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.27 per share. | 14 Apr 2023 | 638 | 68,217 (0%) | 0% | 22.3 | 14,208 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 23.48 per share. | 27 Mar 2023 | 6,433 | 240,506 (0%) | 0% | 23.5 | 151,047 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 26,997 | 1,218,631 (1%) | 0% | 23.7 | 640,369 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 18,428 | 1,245,628 (1%) | 0% | 23.7 | 437,112 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,083 | 264,993 (0%) | 0% | 23.7 | 25,689 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,586 | 263,407 (0%) | 0% | 23.7 | 37,620 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 5,307 | 368,665 (0%) | 0% | 23.7 | 125,882 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 3,622 | 373,972 (0%) | 0% | 23.7 | 85,914 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 3,124 | 246,939 (0%) | 0% | 23.7 | 74,101 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 2,143 | 250,063 (0%) | 0% | 23.7 | 50,832 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,674 | 108,249 (0%) | 0% | 23.7 | 39,707 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,142 | 109,923 (0%) | 0% | 23.7 | 27,088 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 545 | 68,855 (0%) | 0% | 23.7 | 12,927 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 372 | 69,400 (0%) | 0% | 23.7 | 8,824 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 365 | 30,029 (0%) | 0% | 23.7 | 8,658 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 583 | 29,446 (0%) | 0% | 23.7 | 13,829 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 404 | 30,394 (0%) | 0% | 23.7 | 9,583 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 20,046 | 1,264,056 (1%) | 0% | 22.9 | 459,254 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 1,351 | 266,076 (0%) | 0% | 22.9 | 30,951 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 4,074 | 377,594 (0%) | 0% | 22.9 | 93,335 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 2,419 | 252,206 (0%) | 0% | 22.9 | 55,419 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 751 | 50,272 (0%) | 0% | 22.9 | 17,205 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 1,677 | 111,065 (0%) | 0% | 22.9 | 38,420 | Common Stock |
| Pamela Wong | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 1,432 | 72,320 (0%) | 0% | 22.9 | 32,807 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 1,399 | 69,772 (0%) | 0% | 22.9 | 32,051 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 388 | 30,798 (0%) | 0% | 22.9 | 8,889 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 197,023 | 1,284,102 (1%) | 0% | 0 | Common Stock | |
| Mark Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 39,405 | 267,427 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 43,783 | 381,668 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 39,405 | 254,625 (0%) | 0% | 0 | Common Stock | |
| Margaret Ancona | SVP, Chief of Staff | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 16,419 | 51,023 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 28,459 | 112,742 (0%) | 0% | 0 | Common Stock | |
| Pamela Wong | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 21,892 | 73,752 (0%) | 0% | 0 | Common Stock | |
| Dale Muzzey | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 28,459 | 71,171 (0%) | 0% | 0 | Common Stock | |
| Natalie Munk | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 6,000 | 31,186 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.55 per share. | 02 Mar 2023 | 15,000 | 337,885 (0%) | 0% | 22.6 | 338,253 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 22.74 per share. | 02 Mar 2023 | 13,184 | 215,220 (0%) | 0% | 22.7 | 299,823 | Common Stock |
| Margaret Ancona | SVP, Chief of Staff | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.54 per share. | 25 Feb 2023 | 2,556 | 34,604 (0%) | 0% | 18.5 | 47,388 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.54 per share. | 25 Feb 2023 | 1,012 | 84,283 (0%) | 0% | 18.5 | 18,762 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.42 per share. | 18 Feb 2023 | 11,222 | 352,885 (0%) | 0% | 19.4 | 217,931 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.04 per share. | 20 Jan 2023 | 9,400 | 364,107 (0%) | 0% | 20.0 | 188,386 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 18 Jan 2023 | 600 | 373,507 (0%) | 0% | 20.0 | 12,006 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 01 Jan 2023 | 853 | 228,404 (0%) | 0% | 14.5 | 12,377 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.51 per share. | 01 Jan 2023 | 302 | 42,712 (0%) | 0% | 14.5 | 4,382 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.15 per share. | 27 Dec 2022 | 20,000 | 374,107 (0%) | 0% | 15.1 | 302,992 | Common Stock |
| Pamela Wong | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.00 per share. | 18 Oct 2022 | 1,972 | 51,860 (0%) | 0% | 20 | 39,440 | Common Stock |
| Pamela Wong | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.00 per share. | 18 Oct 2022 | 1,346 | 53,832 (0%) | 0% | 20 | 26,920 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 3,360 | 233,028 (0%) | 0% | 19.6 | 65,923 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 5,006 | 228,022 (0%) | 0% | 19.6 | 98,218 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 2,948 | 172,561 (0%) | 0% | 19.6 | 57,840 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 1,978 | 175,509 (0%) | 0% | 19.6 | 38,808 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 7,411 | 394,107 (0%) | 0% | 19.6 | 145,404 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 4,974 | 401,518 (0%) | 0% | 19.6 | 97,590 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 4,867 | 236,508 (0%) | 0% | 19.6 | 95,491 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 7,251 | 229,257 (0%) | 0% | 19.6 | 142,265 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 1,721 | 85,295 (0%) | 0% | 19.6 | 33,766 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 309 | 43,014 (0%) | 0% | 19.6 | 6,063 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 2,793 | 238,681 (0%) | 0% | 18.7 | 52,201 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 2,293 | 236,388 (0%) | 0% | 18.4 | 42,214 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 1,662 | 179,703 (0%) | 0% | 18.7 | 31,063 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 2,216 | 177,487 (0%) | 0% | 18.4 | 40,797 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 4,543 | 406,492 (0%) | 0% | 18.4 | 83,637 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 5,263 | 411,035 (0%) | 0% | 18.7 | 98,365 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 2,950 | 241,375 (0%) | 0% | 18.4 | 54,310 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 642 | 244,325 (0%) | 0% | 18.7 | 11,999 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 862 | 87,016 (0%) | 0% | 18.4 | 15,869 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 346 | 87,878 (0%) | 0% | 18.7 | 6,467 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 345 | 43,456 (0%) | 0% | 18.7 | 6,448 | Common Stock |
| Dale Muzzey | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 133 | 43,323 (0%) | 0% | 18.4 | 2,449 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.20 per share. | 21 Sep 2022 | 702 | 241,474 (0%) | 0% | 20.2 | 14,180 | Common Stock |
| Mark Verratti | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 25 Aug 2022 | 1,031 | 242,176 (0%) | 0% | 24.9 | 25,662 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 25 Aug 2022 | 1,146 | 181,365 (0%) | 0% | 24.9 | 28,524 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 25 Aug 2022 | 3,056 | 416,298 (0%) | 0% | 24.9 | 76,064 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Aug 2022 | 2,150 | 419,354 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 25 Aug 2022 | 1,132 | 244,967 (0%) | 0% | 24.9 | 28,175 | Common Stock |
| Natalie Munk | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.89 per share. | 25 Aug 2022 | 220 | 25,186 (0%) | 0% | 24.9 | 5,476 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.61 per share. | 13 Aug 2022 | 49,980 | 1,087,079 (1%) | 0% | 27.6 | 1,379,948 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.61 per share. | 13 Aug 2022 | 22,370 | 1,137,059 (1%) | 0% | 27.6 | 617,636 | Common Stock |
| Jayne B. Hart | Chief People Officer | Grant, award, or other acquisition of securities at price $ 14.84 per share. | 09 Jun 2022 | 1,036 | 182,511 (0%) | 0% | 14.8 | 15,375 | Common Stock |
| Daniel K. Spiegelman | Director | Sale of securities on an exchange or to another person at price $ 19.25 per share. | 06 Jun 2022 | 6,424 | 33,980 (0%) | 0% | 19.3 | 123,673 | Common Stock |
| Daniel K. Spiegelman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 40,404 (0%) | 0% | 0 | Common Stock | |
| Dennis H. Langer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 106,802 (0%) | 0% | 0 | Common Stock | |
| Heiner Dreismann | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 100,802 (0%) | 0% | 0 | Common Stock | |
| S. Louise Phanstiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 96,802 (0%) | 0% | 0 | Common Stock | |
| Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 55,164 (0%) | 0% | 0 | Common Stock | |
| Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 57,699 (0%) | 0% | 0 | Common Stock | |
| Lee N. Newcomer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 57,699 (0%) | 0% | 0 | Common Stock | |
| Rashmi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 17,275 | 54,046 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 10,000 | 243,207 (0%) | 0% | 0 | Common Stock | |
| Eric Santa | Chief Growth Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.88 per share. | 01 Apr 2022 | 1,769 | 56,734 (0%) | 0% | 25.9 | 45,782 | Common Stock |
| Eric Santa | Chief Growth Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.88 per share. | 01 Apr 2022 | 1,207 | 58,503 (0%) | 0% | 25.9 | 31,237 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 17,884 | 1,185,629 (1%) | 0% | 25.3 | 452,823 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 26,200 | 1,159,429 (1%) | 0% | 25.3 | 663,384 | Common Stock |
| Mark Verratti | President, Mental Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,584 | 233,207 (0%) | 0% | 25.3 | 40,107 | Common Stock |
| Mark Verratti | President, Mental Health | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,082 | 234,791 (0%) | 0% | 25.3 | 27,396 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 2,164 | 181,475 (0%) | 0% | 25.3 | 54,792 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,477 | 183,639 (0%) | 0% | 25.3 | 37,398 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 3,633 | 426,827 (0%) | 0% | 25.3 | 91,988 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 5,323 | 421,504 (0%) | 0% | 25.3 | 134,778 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 3,178 | 246,099 (0%) | 0% | 25.3 | 80,467 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 2,169 | 249,277 (0%) | 0% | 25.3 | 54,919 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,689 | 88,224 (0%) | 0% | 25.3 | 42,765 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,153 | 89,913 (0%) | 0% | 25.3 | 29,194 | Common Stock |
| Paul J. Diaz | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 173,144 | 1,203,513 (1%) | 0% | 0 | Common Stock | |
| Mark Verratti | President, Mental Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 19,238 | 235,873 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 19,238 | 185,116 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 36,866 | 430,460 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 33,665 | 251,446 (0%) | 0% | 0 | Common Stock | |
| Margaret Ancona | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 9,754 | 37,160 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 19,238 | 91,066 (0%) | 0% | 0 | Common Stock | |
| Eric Santa | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 19,238 | 59,710 (0%) | 0% | 0 | Common Stock | |
| Pamela Wong | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 16,353 | 55,178 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 28 Feb 2022 | 7,000 | 165,878 (0%) | 0% | 25 | 175,000 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.98 per share. | 28 Feb 2022 | 7,000 | 172,878 (0%) | 0% | 24.0 | 167,860 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 7,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 3,500 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Jayne B. Hart | Chief People Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 28 Feb 2022 | 3,500 | 165,878 (0%) | 0% | 25 | 87,500 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.98 per share. | 28 Feb 2022 | 3,500 | 169,378 (0%) | 0% | 24.0 | 83,930 | Common Stock |
| Margaret Ancona | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.69 per share. | 25 Feb 2022 | 2,594 | 27,406 (0%) | 0% | 24.7 | 64,046 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.69 per share. | 25 Feb 2022 | 865 | 71,828 (0%) | 0% | 24.7 | 21,357 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 234,271 | 1,030,369 (1%) | 0% | 0 | Common Stock | |
| Mark Verratti | President, Mental Health | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 22,616 | 216,635 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 19,520 | 165,878 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 48,009 | 404,774 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.69 per share. | 16 Feb 2022 | 11,180 | 393,594 (0%) | 0% | 25.7 | 287,214 | Common Stock |
| Nicole Lambert | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 43,295 | 217,781 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 19,520 | 72,693 (0%) | 0% | 0 | Common Stock | |
| Eric Santa | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 24,052 | 40,472 (0%) | 0% | 0 | Common Stock | |
| Pamela Wong | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 23,072 | 38,825 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Grant, award, or other acquisition of securities at price $ 21.98 per share. | 30 Nov 2021 | 143 | 146,358 (0%) | 0% | 22.0 | 3,143 | Common Stock |
| Pamela Wong | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 15,753 | 15,753 (0%) | 0% | 0 | Common Stock | |
| Jerry S. Lanchbury | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 6,470 | 264,324 (0%) | 0% | 30.9 | 199,794 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 4,341 | 270,794 (0%) | 0% | 30.9 | 134,050 | Common Stock |
| Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 3,349 | 199,010 (0%) | 0% | 30.9 | 103,417 | Common Stock |
| Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 4,991 | 194,019 (0%) | 0% | 30.9 | 154,122 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 1,978 | 149,163 (0%) | 0% | 30.9 | 61,081 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 2,948 | 146,215 (0%) | 0% | 30.9 | 91,034 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 7,419 | 356,765 (0%) | 0% | 30.9 | 229,099 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 4,979 | 364,184 (0%) | 0% | 30.9 | 153,752 | Common Stock |
| Nicole Lambert | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 5,013 | 171,639 (0%) | 0% | 30.9 | 154,801 | Common Stock |
| Nicole Lambert | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 7,470 | 164,169 (0%) | 0% | 30.9 | 230,674 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 1,729 | 53,173 (0%) | 0% | 30.9 | 53,392 | Common Stock |
| Nicole Lambert | See Remarks | Sale of securities on an exchange or to another person at price $ 31.57 per share. | 01 Oct 2021 | 1,420 | 176,652 (0%) | 0% | 31.6 | 44,835 | Common Stock |
| Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 6,746 | 205,873 (0%) | 0% | 33.3 | 224,709 | Common Stock |
| Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 3,514 | 202,359 (0%) | 0% | 33.3 | 117,051 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 2,216 | 110,120 (0%) | 0% | 33.3 | 73,815 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 3,878 | 112,336 (0%) | 0% | 33.3 | 129,176 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 11,907 | 373,704 (0%) | 0% | 33.3 | 396,622 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 4,541 | 369,163 (0%) | 0% | 33.3 | 151,261 | Common Stock |
| Nicole Lambert | See Remarks | Sale of securities on an exchange or to another person at price $ 33.10 per share. | 25 Sep 2021 | 10,112 | 178,072 (0%) | 0% | 33.1 | 334,747 | Common Stock |
| Nicole Lambert | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 1,311 | 191,610 (0%) | 0% | 33.3 | 43,669 | Common Stock |
| Nicole Lambert | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 3,426 | 188,184 (0%) | 0% | 33.3 | 114,120 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 865 | 54,902 (0%) | 0% | 33.3 | 28,813 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 346 | 55,767 (0%) | 0% | 33.3 | 11,525 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.06 per share. | 23 Sep 2021 | 200 | 288,515 (0%) | 0% | 35.1 | 7,012 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 23 Sep 2021 | 3,633 | 275,135 (0%) | 0% | 33.3 | 121,015 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 23 Sep 2021 | 9,747 | 278,768 (0%) | 0% | 33.3 | 324,673 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2021 | 445,439 | 845,488 (1%) | 0% | 0 | Common Stock | |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 23 Sep 2021 | 49,390 | 796,098 (1%) | 0% | 34.8 | 1,716,796 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 58,398 | 288,715 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | President, Myriad Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 46,571 | 212,619 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | President, Myriad Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 10,000 | 166,048 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 26,598 | 116,214 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 66,977 | 385,611 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2021 | 65,870 | 192,921 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 17 Sep 2021 | 73,225 | 153,287 (0%) | 0% | 26.5 | 1,939,730 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2021 | 73,225 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2021 | 3,775 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Jayne B. Hart | Chief People Officer | Sale of securities on an exchange or to another person at price $ 33.72 per share. | 17 Sep 2021 | 2,966 | 89,616 (0%) | 0% | 33.7 | 100,014 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 17 Sep 2021 | 3,775 | 92,582 (0%) | 0% | 26.5 | 100,000 | Common Stock |
| Jayne B. Hart | Chief People Officer | Sale of securities on an exchange or to another person at price $ 33.72 per share. | 17 Sep 2021 | 64,480 | 88,807 (0%) | 0% | 33.7 | 2,174,266 | Common Stock |
| Nicole Lambert | See Remarks | Sale of securities on an exchange or to another person at price $ 34.50 per share. | 27 Aug 2021 | 945 | 127,051 (0%) | 0% | 34.5 | 32,603 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.81 per share. | 25 Aug 2021 | 2,233 | 230,317 (0%) | 0% | 34.8 | 77,731 | Common Stock |
| Mark Verratti | President, Myriad Neuroscience | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.81 per share. | 25 Aug 2021 | 1,082 | 156,048 (0%) | 0% | 34.8 | 37,664 | Common Stock |
| Jayne B. Hart | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.81 per share. | 25 Aug 2021 | 1,148 | 80,062 (0%) | 0% | 34.8 | 39,962 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Aug 2021 | 3,250 | 321,692 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.81 per share. | 25 Aug 2021 | 3,058 | 318,634 (0%) | 0% | 34.8 | 106,449 | Common Stock |
| Nicole Lambert | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.81 per share. | 25 Aug 2021 | 1,123 | 127,996 (0%) | 0% | 34.8 | 39,092 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.07 per share. | 23 Aug 2021 | 10,000 | 242,550 (0%) | 0% | 27.1 | 270,700 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 30,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 40,000 | 30,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 10,000 | 70,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.57 per share. | 23 Aug 2021 | 30,000 | 232,550 (0%) | 0% | 35.6 | 1,067,100 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.07 per share. | 23 Aug 2021 | 30,000 | 262,550 (0%) | 0% | 27.1 | 812,100 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.07 per share. | 23 Aug 2021 | 40,000 | 232,550 (0%) | 0% | 35.1 | 1,402,800 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.07 per share. | 23 Aug 2021 | 40,000 | 272,550 (0%) | 0% | 27.1 | 1,082,800 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.57 per share. | 23 Aug 2021 | 10,000 | 232,550 (0%) | 0% | 35.6 | 355,700 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.79 per share. | 13 Aug 2021 | 58,820 | 400,049 (0%) | 0% | 32.8 | 1,928,708 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.57 per share. | 05 Aug 2021 | 28,225 | 232,550 (0%) | 0% | 35.6 | 1,004,008 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 28,225 | 80,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.07 per share. | 05 Aug 2021 | 28,225 | 260,775 (0%) | 0% | 27.1 | 764,051 | Common Stock |
| S. Louise Phanstiel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.29 per share. | 05 Aug 2021 | 30,000 | 91,646 (0%) | 0% | 21.3 | 638,700 | Common Stock |
| S. Louise Phanstiel | Director | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 05 Aug 2021 | 47,881 | 61,646 (0%) | 0% | 35.0 | 1,677,741 | Common Stock |
| S. Louise Phanstiel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.39 per share. | 05 Aug 2021 | 30,000 | 109,527 (0%) | 0% | 25.4 | 761,700 | Common Stock |
| S. Louise Phanstiel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 30,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| S. Louise Phanstiel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 30,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Dennis H. Langer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 30,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Dennis H. Langer | Director | Sale of securities on an exchange or to another person at price $ 34.75 per share. | 03 Aug 2021 | 30,000 | 89,527 (0%) | 0% | 34.8 | 1,042,500 | Common Stock |
| Dennis H. Langer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.39 per share. | 03 Aug 2021 | 30,000 | 119,527 (0%) | 0% | 25.4 | 761,700 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.07 per share. | 03 Aug 2021 | 38,225 | 270,775 (0%) | 0% | 27.1 | 1,034,751 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 11,775 | 108,225 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 38,225 | 120,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 1,775 | 158,225 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 16,225 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 27,830 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2021 | 4,170 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.57 per share. | 03 Aug 2021 | 11,775 | 232,550 (0%) | 0% | 35.6 | 418,856 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.07 per share. | 03 Aug 2021 | 11,775 | 244,325 (0%) | 0% | 27.1 | 318,749 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.24 per share. | 03 Aug 2021 | 38,225 | 232,550 (0%) | 0% | 35.2 | 1,347,171 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.98 per share. | 03 Aug 2021 | 4,170 | 236,720 (0%) | 0% | 24.0 | 99,997 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 03 Aug 2021 | 27,830 | 232,550 (0%) | 0% | 34 | 946,220 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.98 per share. | 03 Aug 2021 | 27,830 | 260,380 (0%) | 0% | 24.0 | 667,363 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.07 per share. | 03 Aug 2021 | 1,775 | 232,550 (0%) | 0% | 35.1 | 62,249 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.07 per share. | 03 Aug 2021 | 1,775 | 234,325 (0%) | 0% | 27.1 | 48,049 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.99 per share. | 03 Aug 2021 | 16,225 | 232,550 (0%) | 0% | 34.0 | 551,488 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 03 Aug 2021 | 16,225 | 248,775 (0%) | 0% | 26.5 | 429,800 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 03 Aug 2021 | 4,170 | 232,550 (0%) | 0% | 34 | 141,780 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.14 per share. | 03 Aug 2021 | 14,983 | 324,942 (0%) | 0% | 35.1 | 526,476 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 3,295 | 56,225 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 12 Jul 2021 | 36,705 | 269,255 (0%) | 0% | 26.5 | 972,315 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.55 per share. | 12 Jul 2021 | 36,705 | 232,550 (0%) | 0% | 33.5 | 1,231,431 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 12 Jul 2021 | 13,295 | 245,845 (0%) | 0% | 26.5 | 352,185 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.55 per share. | 12 Jul 2021 | 13,295 | 232,550 (0%) | 0% | 33.6 | 446,075 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 12 Jul 2021 | 3,295 | 235,845 (0%) | 0% | 26.5 | 87,285 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.69 per share. | 12 Jul 2021 | 3,295 | 232,550 (0%) | 0% | 33.7 | 111,012 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 12 Jul 2021 | 40,000 | 272,550 (0%) | 0% | 26.5 | 1,059,600 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.74 per share. | 12 Jul 2021 | 40,000 | 232,550 (0%) | 0% | 33.7 | 1,349,756 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 36,705 | 72,815 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 13,295 | 59,520 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 40,000 | 16,225 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 09 Jul 2021 | 26,705 | 259,255 (0%) | 0% | 26.5 | 707,415 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2021 | 5,603 | 109,520 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2021 | 26,705 | 115,123 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2021 | 17,692 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 09 Jul 2021 | 17,692 | 232,550 (0%) | 0% | 32.5 | 574,459 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.47 per share. | 09 Jul 2021 | 17,692 | 250,242 (0%) | 0% | 19.5 | 344,463 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.29 per share. | 09 Jul 2021 | 5,603 | 232,550 (0%) | 0% | 32.3 | 180,921 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 09 Jul 2021 | 5,603 | 238,153 (0%) | 0% | 26.5 | 148,423 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.79 per share. | 09 Jul 2021 | 26,705 | 232,550 (0%) | 0% | 32.8 | 875,657 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.29 per share. | 07 Jul 2021 | 30,424 | 232,550 (0%) | 0% | 32.3 | 982,391 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2021 | 30,424 | 141,828 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2021 | 1,884 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.99 per share. | 07 Jul 2021 | 1,884 | 232,550 (0%) | 0% | 32.0 | 60,269 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 07 Jul 2021 | 1,884 | 234,434 (0%) | 0% | 26.5 | 49,907 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 07 Jul 2021 | 30,424 | 262,974 (0%) | 0% | 26.5 | 805,932 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.43 per share. | 28 Jun 2021 | 3,973 | 232,550 (0%) | 0% | 32.4 | 128,855 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 3,973 | 172,252 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 948 | 17,692 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2021 | 1,891 | 1,884 | - | - | Incentive Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.49 per share. | 28 Jun 2021 | 948 | 232,550 (0%) | 0% | 32.5 | 30,804 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.47 per share. | 28 Jun 2021 | 948 | 233,498 (0%) | 0% | 19.5 | 18,458 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.23 per share. | 28 Jun 2021 | 1,891 | 232,550 (0%) | 0% | 32.2 | 60,950 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 28 Jun 2021 | 1,891 | 234,441 (0%) | 0% | 26.5 | 50,093 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 28 Jun 2021 | 3,973 | 236,523 (0%) | 0% | 26.5 | 105,245 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 25 Jun 2021 | 21,360 | 265,922 (0%) | 0% | 32.5 | 693,559 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 28,640 | 18,640 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 21,360 | 47,280 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.61 per share. | 25 Jun 2021 | 33,372 | 232,550 (0%) | 0% | 31.6 | 1,055,036 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.97 per share. | 25 Jun 2021 | 28,640 | 265,922 (0%) | 0% | 32.0 | 915,621 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.47 per share. | 25 Jun 2021 | 28,640 | 294,562 (0%) | 0% | 19.5 | 557,621 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.47 per share. | 25 Jun 2021 | 21,360 | 287,282 (0%) | 0% | 19.5 | 415,879 | Common Stock |
| Daniel K. Spiegelman | Director | Sale of securities on an exchange or to another person at price $ 30.52 per share. | 17 Jun 2021 | 3,139 | 23,129 (0%) | 0% | 30.5 | 95,795 | Common Stock |
| Dreismann Heinrich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 12,848 | 83,527 (0%) | 0% | 0 | Common Stock | |
| Lee N. Newcomer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 12,848 | 40,424 (0%) | 0% | 0 | Common Stock | |
| Rashmi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 12,848 | 36,771 (0%) | 0% | 0 | Common Stock | |
| Daniel K. Spiegelman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 12,848 | 26,268 (0%) | 0% | 0 | Common Stock | |
| Dennis H. Langer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 12,848 | 89,527 (0%) | 0% | 0 | Common Stock | |
| Daniel K. Spiegelman | Director | Sale of securities on an exchange or to another person at price $ 28.99 per share. | 28 May 2021 | 7,142 | 13,420 (0%) | 0% | 29.0 | 207,023 | Common Stock |
| Jayne B. Hart | Chief People Officer | Grant, award, or other acquisition of securities at price $ 15.86 per share. | 28 May 2021 | 1,082 | 81,210 (0%) | 0% | 15.9 | 17,162 | Common Stock |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 15.86 per share. | 28 May 2021 | 344 | 56,113 (0%) | 0% | 15.9 | 5,456 | Common Stock |
| Daniel K. Spiegelman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 May 2021 | 15,889 | 20,562 (0%) | 0% | 0 | Common Stock | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.47 per share. | 04 May 2021 | 19,360 | 285,282 (0%) | 0% | 19.5 | 376,939 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2021 | 19,360 | 68,640 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.97 per share. | 04 May 2021 | 19,360 | 265,922 (0%) | 0% | 32.0 | 618,949 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.47 per share. | 27 Apr 2021 | 40,000 | 265,922 (0%) | 0% | 31.5 | 1,258,800 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Apr 2021 | 40,000 | 88,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.47 per share. | 27 Apr 2021 | 40,000 | 305,922 (0%) | 0% | 19.5 | 778,800 | Common Stock |
| Nicole Lambert | See Remarks | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 19 Apr 2021 | 5,890 | 129,119 (0%) | 0% | 27.0 | 159,086 | Common Stock |
| Nicole Lambert | See Remarks | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 19 Apr 2021 | 759 | 135,009 (0%) | 0% | 27.0 | 20,500 | Common Stock |
| Eric Santa | Chief Growth Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 16,420 | 16,420 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2021 | 28,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2021 | 21,966 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Mar 2021 | 8,034 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Jayne B. Hart | Chief People Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 29 Mar 2021 | 8,034 | 80,128 (0%) | 0% | 30 | 241,020 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.89 per share. | 29 Mar 2021 | 8,034 | 88,162 (0%) | 0% | 24.9 | 199,966 | Common Stock |
| Jayne B. Hart | Chief People Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 29 Mar 2021 | 21,966 | 80,128 (0%) | 0% | 30 | 658,980 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.89 per share. | 29 Mar 2021 | 21,966 | 102,094 (0%) | 0% | 24.9 | 546,734 | Common Stock |
| Jayne B. Hart | Chief People Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 29 Mar 2021 | 28,000 | 80,128 (0%) | 0% | 30 | 840,000 | Common Stock |
| Jayne B. Hart | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.47 per share. | 29 Mar 2021 | 28,000 | 108,128 (0%) | 0% | 19.5 | 545,160 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 19,347 | 265,922 (0%) | 0% | 0 | Common Stock | |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 159,915 | 458,869 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | President, Myriad Neuroscience | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 15,441 | 157,130 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 13,326 | 80,128 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 32,774 | 339,925 (0%) | 0% | 0 | Common Stock | |
| Benjamin Jackson | E.V.P., General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 18,879 | 107,029 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | President, Myriad Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 29,556 | 135,768 (0%) | 0% | 0 | Common Stock | |
| Paul Chip Parkinson | EVP Strategy and Innovation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 10,661 | 87,407 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 13,326 | 55,769 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 29.69 per share. | 18 Feb 2021 | 11,175 | 307,151 (0%) | 0% | 29.7 | 331,786 | Common Stock |
| Margaret Ancona | SVP Enterprise Transformation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 30,000 | 30,000 (0%) | 0% | 0 | Common Stock | |
| Kevin Richard Haas | SVP Technology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 10,000 | 42,443 (0%) | 0% | 0 | Common Stock | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.71 per share. | 16 Feb 2021 | 74,445 | 246,575 (0%) | 0% | 29.7 | 2,211,992 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 16 Feb 2021 | 74,445 | 321,020 (0%) | 0% | 18 | 1,340,010 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 74,445 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 5,555 | 0 | - | - | Incentive Stock Option (right to buy) | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.71 per share. | 16 Feb 2021 | 5,555 | 246,575 (0%) | 0% | 29.7 | 165,056 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.00 per share. | 16 Feb 2021 | 5,555 | 252,130 (0%) | 0% | 18 | 99,990 | Common Stock |
| Paul Chip Parkinson | EVP Strategy and Innovation | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Jan 2021 | 11,824 | 76,746 (0%) | 0% | 25 | 295,600 | Common Stock |
| S. Louise Phanstiel | Director | Purchase of securities on an exchange or from another person at price $ 16.62 per share. | 11 Nov 2020 | 15,000 | 66,790 (0%) | 0% | 16.6 | 249,336 | Common Stock |
| Paul C. Parkinson | EVP Strategy and Innovation | Sale or transfer of securities back to the company at price $ 12.43 per share. | 31 Oct 2020 | 2,218 | 88,570 (0%) | 0% | 12.4 | 27,570 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 39,196 | 246,575 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | President Assurex Health Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 31,258 | 141,689 (0%) | 0% | 0 | Common Stock | |
| Jayne B. Hart | Executive VP Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 17,853 | 66,802 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 44,954 | 318,326 (0%) | 0% | 0 | Common Stock | |
| Benjamin Jackson | E.V.P., General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 29,784 | 88,150 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | President, MGL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 44,211 | 106,212 (0%) | 0% | 0 | Common Stock | |
| Paul C. Parkinson | EVP Strategy and Innovation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 21,730 | 90,788 (0%) | 0% | 0 | Common Stock | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 5,544 | 207,379 (0%) | 0% | 13.0 | 72,294 | Common Stock |
| Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 725 | 110,431 (0%) | 0% | 13.0 | 9,454 | Common Stock |
| Jayne B. Hart | Executive VP Human Resources | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 2,218 | 48,949 (0%) | 0% | 13.0 | 28,923 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 6,653 | 273,372 (0%) | 0% | 13.0 | 86,755 | Common Stock |
| Alexander Ford | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 6,653 | 169,040 (0%) | 0% | 13.0 | 86,755 | Common Stock |
| Benjamin Jackson | E.V.P., General Counsel | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 416 | 58,366 (0%) | 0% | 13.0 | 5,425 | Common Stock |
| Nicole Lambert | President, MGL | Sale or transfer of securities back to the company at price $ 13.04 per share. | 30 Sep 2020 | 591 | 62,001 (0%) | 0% | 13.0 | 7,707 | Common Stock |
| Jayne B. Hart | Executive VP Human Resources | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 2,218 | 55,049 (0%) | 0% | 12.4 | 27,592 | Common Stock |
| Jayne B. Hart | Executive VP Human Resources | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 2,218 | 51,167 (0%) | 0% | 12.4 | 27,592 | Common Stock |
| Jayne B. Hart | Executive VP Human Resources | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 1,664 | 53,385 (0%) | 0% | 12.4 | 20,700 | Common Stock |
| Benjamin Jackson | E.V.P., General Counsel | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 2,935 | 58,782 (0%) | 0% | 12.4 | 36,511 | Common Stock |
| Benjamin Jackson | E.V.P., General Counsel | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 367 | 62,170 (0%) | 0% | 12.4 | 4,565 | Common Stock |
| Benjamin Jackson | E.V.P., General Counsel | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 453 | 61,717 (0%) | 0% | 12.4 | 5,635 | Common Stock |
| Nicole Lambert | President, MGL | Sale or transfer of securities back to the company at price $ 12.46 per share. | 25 Sep 2020 | 13 | 66,155 (0%) | 0% | 12.5 | 162 | Common Stock |
| Nicole Lambert | President, MGL | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 628 | 66,168 (0%) | 0% | 12.4 | 7,812 | Common Stock |
| Nicole Lambert | President, MGL | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 2,935 | 62,592 (0%) | 0% | 12.4 | 36,511 | Common Stock |
| Nicole Lambert | President, MGL | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 628 | 65,527 (0%) | 0% | 12.4 | 7,812 | Common Stock |
| Paul C. Parkinson | EVP Strategy and Innovation | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 3,327 | 69,058 (0%) | 0% | 12.4 | 41,388 | Common Stock |
| Paul C. Parkinson | EVP Strategy and Innovation | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 2,218 | 72,385 (0%) | 0% | 12.4 | 27,592 | Common Stock |
| Paul C. Parkinson | EVP Strategy and Innovation | Sale or transfer of securities back to the company at price $ 12.44 per share. | 25 Sep 2020 | 2,218 | 74,603 (0%) | 0% | 12.4 | 27,592 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 5,544 | 220,764 (0%) | 0% | 12.4 | 68,967 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 32,800 | 226,308 (0%) | 0% | 0 | Common Stock | |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 4,214 | 216,550 (0%) | 0% | 12.4 | 52,422 | Common Stock |
| Jerry S. Lanchbury | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 3,627 | 212,923 (0%) | 0% | 12.4 | 45,120 | Common Stock |
| Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 2,897 | 113,532 (0%) | 0% | 12.4 | 36,039 | Common Stock |
| Mark Verratti | President Assurex Health Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 32,800 | 119,326 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 2,376 | 111,156 (0%) | 0% | 12.4 | 29,557 | Common Stock |
| Mark Verratti | President Assurex Health Inc. | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 2,897 | 116,429 (0%) | 0% | 12.4 | 36,039 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 4,546 | 280,025 (0%) | 0% | 12.4 | 56,552 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 6,653 | 284,571 (0%) | 0% | 12.4 | 82,763 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 5,267 | 291,224 (0%) | 0% | 12.4 | 65,521 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 41,000 | 296,491 (0%) | 0% | 0 | Common Stock | |
| Alexander Ford | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 5,267 | 180,239 (0%) | 0% | 12.4 | 65,521 | Common Stock |
| Alexander Ford | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 6,653 | 185,506 (0%) | 0% | 12.4 | 82,763 | Common Stock |
| Alexander Ford | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 12.44 per share. | 24 Sep 2020 | 4,546 | 175,693 (0%) | 0% | 12.4 | 56,552 | Common Stock |
| Alexander Ford | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 41,000 | 192,159 (0%) | 0% | 0 | Common Stock | |
| Rashmi Kumar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2020 | 23,923 | 23,923 (0%) | 0% | 0 | Common Stock | |
| Alexander Ford | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 13.78 per share. | 15 Sep 2020 | 2,804 | 151,159 (0%) | 0% | 13.8 | 38,630 | Common Stock |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2020 | 342,040 | 342,040 | - | - | Time-Based Stock Option | |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2020 | 298,954 | 298,954 (0%) | 0% | 0 | Common Stock | |
| Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2020 | 339,088 | 339,088 | - | - | Performance-Based Stock Option | |
| Jerry S. Lanchbury | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2020 | 10,068 | 193,508 (0%) | 0% | 0 | Common Stock | |
| Mark Verratti | President Assurex Health Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2020 | 7,467 | 86,526 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2020 | 13,787 | 255,491 (0%) | 0% | 0 | Common Stock | |
| Alexander Ford | President, MWH | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2020 | 11,525 | 153,963 (0%) | 0% | 0 | Common Stock | |
| Benjamin Jackson | E.V.P., General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2020 | 6,541 | 62,537 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | President, MGL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2020 | 7,646 | 66,796 (0%) | 0% | 0 | Common Stock | |
| Daniel M. Skovronsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2020 | 25,041 | 25,041 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Gift of securities by or to the insider at price $ 29.91 per share. | 30 Jun 2020 | 2,000 | 142,204 (0%) | 0% | 29.9 | 59,820 | Common Stock |
| R. Bryan Riggsbee | Chief Financial Officer | Gift of securities by or to the insider at price $ 30.39 per share. | 30 Jun 2020 | 500 | 141,704 (0%) | 0% | 30.4 | 15,195 | Common Stock |
| Daniel K. Spiegelman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 20,562 | 20,562 (0%) | 0% | 0 | Common Stock | |
| R. Bryan Riggsbee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2020 | 100,000 | 244,204 (0%) | 0% | 0 | Common Stock | |
| Nicole Lambert | President, MGL | Sale of securities on an exchange or to another person at price $ 19.73 per share. | 12 Feb 2020 | 4,354 | 59,150 (0%) | 0% | 19.7 | 85,915 | Common Stock |
| Alexander Ford | President, MWH | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 05 Feb 2020 | 7,273 | 142,438 (0%) | 0% | 30 | 218,190 | Common Stock |
| Alexander Ford | President, MWH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.98 per share. | 26 Dec 2019 | 1,307 | 149,711 (0%) | 0% | 16.0 | 20,886 | Common Stock |
| Alexander Ford | President, MWH | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2019 | 1,307 | 2,693 | - | - | Incentive Stock Option (right to buy) | |
| Walter Gilbert | Director | Purchase of securities on an exchange or from another person at price $ 25.60 per share. | 13 Dec 2019 | 5,860 | 54,150 (0%) | 0% | 25.6 | 149,998 | Common Stock |
| Dennis H. Langer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 60,790 (0%) | 0% | 0 | Common Stock | |
| John T. Henderson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 76,040 (0%) | 0% | 0 | Common Stock | |
| Lawrence C. Best | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 60,790 (0%) | 0% | 0 | Common Stock | |
| Walter Gilbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 48,290 (0%) | 0% | 0 | Common Stock | |
| Dreismann Heinrich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 54,790 (0%) | 0% | 0 | Common Stock | |
| S. Louise Phanstiel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 51,790 (0%) | 0% | 0 | Common Stock | |
| Colleen F. Reitan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 11,687 (0%) | 0% | 0 | Common Stock | |
| Lee N. Newcomer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2019 | 11,687 | 11,687 (0%) | 0% | 0 | Common Stock |